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When testing the response to &-agonist drugs in severe chronic obstructive pulmonary disease (COPD), a 
dose-response assessment should be undertaken. This study compares the time course of inhaled salmeterol 
(25, 50 and 75 pug) and formoterol (12, 24 and 36 pug) at different doses in a group of 12 patients with partially 
reversible, but severe COPD (FEV, of 12-320/O of predicted values after &agonist drugs had been withheld 
for 24 h). All doses of salmeterol and formoterol induced a significant (PcO.01) spirometric improvement over 
the 12-h monitoring period, when compared to the spirometric improvement after placebo, but while 
formoterol induced a dose-dependent increase of the FVC, FEV, and FEF,,, this was not the case for 
salmeterol. In fact, 75 pug salmeterol did not produce a further improvement of these parameters. Mean peak 
bronchodilation, expressed as the increase in FEV, over baseline values, occurred 2 h after inhalation of the 
three doses of salmeterol, and 1 h after inhalation of the three doses of formoterol. A comparison of 5Opg 
salmeterol with 12 pg or 24 pg formoterol (clinically recommended doses), showed that improvement of FEV, 
after salmeterol was statistically (PcO.05) higher than that after the two doses of formoterol, although the 
mean peak bronchodilations were similar. This was because salmeterol has a longer duration of action than 
formoterol. These data demonstrate that salmeterol is equally effective as, but longer-acting than, formoterol 
at clinically recommended doses in patients suffering from COPD, with severe airway obstruction. Moreover, 
these data suggest that 50,~g is the best dosage for salmeterol in these patients. 
Introduction 
The aim of bronchodilator therapy in patients with 
chronic obstructive pulmonary disease (COPD) is to 
treat any airflow obstruction which is reversible (1). 
However, clinicians are sometimes reluctant to 
prescribe &agonists to these patients because the 
airflow obstruction is often ‘irreversible’. Indeed, the 
response to inhaled ,&agonists varies among patients 
with chronic bronchitis and emphysema, presumably 
reflecting the different mechanisms responsible for 
airway obstruction, e.g. smooth muscle-induced 
bronchospasm and luminal obstruction in patients 
with predominant bronchitis KY. airway collapse in 
patients with emphysema, but also because the dose 
of bronchodilator is inadequate for the severity of the 
airflow obstruction. 
Received 15 July 1994 and accepted in revised form 25 October 1994. 
$Author to whom correspondence should be addressed at: Via del 
Parco Margherita 24, 80121 Napoli, Italy. 
0954-61 I l/95/050357+06 $08.00/O 
When the response to &-agonist drugs in severe 
COPD is tested, a dose-response assessment should 
be undertaken. In fact, in patients classified as 
chronic bronchitics, there is clearly a wide variation 
of response to bronchodilators and a surprising 
degree of reversibility can be achieved. Due to this 
variation in response, conventional drug doses may 
be too small in some cases (2). Barclay et al. (2) 
demonstrated that a group of chronic obstructive 
bronchitics were non-responsive to 200,~g inhaled 
salbutamol, but by gradually increasing the dose, a 
response was obtained in all patients. Similar results 
were reported by other authors (3). 
Salmeterol and formoterol are new, highly potent 
&adrenoceptor agonists characterized by a long 
duration of action when inhaled (4). Clinical efficacy 
of these two bronchodilators indicate that they might 
be a major step forward in the therapy of chronic 
reversible airway disease, exceeding the therapeutic 
efficacy of the &agonists available to date (5-7). 
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Table I Anthropometric data and pulmonary function of patients 
Patient Sex 
Age Height 
(years) (cm) 
Weight 
(kg) 
FEV, 
(1) 
FEV, 
(% predicted) 
% 
reversibility 
1 M 62 165 74 0.45 16 +31 
2 M 63 154 46 0.32 14 +34 
3 M 58 157 47 0.68 26 +43 
4 M 61 163 62 0.82 32 +40 
5 M 66 168 80 0.50 18 +20 
6 M 62 164 74 0.50 18 +34 
7 M 64 162 77 0.59 22 +27 
8 M 51 168 81 0.98 32 +24 
9 M 53 160 54 0.52 18 +25 
10 M 74 167 49 0.51 20 +25 
11 M 58 165 54 0.89 30 +20 
12 M 67 154 100 0.25 12 +24 
Moreover, salmeterol has been demonstrated to lead 
to a long lasting improvement of exercise capacity in 
patients with COPD (8). 
In this study, comparisons have been made 
between the time course of inhaled salmeterol and 
formoterol at different doses, in a group of patients 
with partially reversible COPD. 
Patients and Methods 
Twelve male patients with severe COPD partici- 
pated in the study after giving their informed con- 
sent. All fulfilled the criteria proposed by the 
American Thoracic Society (9): i.e. they were current 
or former smokers without a history of asthmatic 
attacks, reporting either chronic cough with or with- 
out sputum production or dyspnoea when walking 
quietly on level ground, or both, were non-atopic, 
had had no change in symptom severity or treatment 
in the preceding 4 weeks, had shown no signs of a 
respiratory tract infection in the month preceding or 
during the trial, were not taking oral corticosteroids 
and had a FEV, between 12-32X (after &agonist 
drugs had been withheld for 24 h) of predicted values. 
Only patients who had an increase in FEV, of at 
least 150/o, 15 min after inhalation of 2OOpg sal- 
butamol from a metered dose inhaler, but a post- 
bronchodilator FEV, or FEV,IFVC below the 
predicted range, were included. Table 1 outlines the 
baseline characteristics of the population studied. 
The study, approved by the Ethics Committee at 
the A. Cardarelli Hospital of Naples, was performed 
using a single-blind, cross-over, randomized study. 
The bronchodilator activity of 25, 50 and 75,ug 
salmeterol hydroxynaphthoate (Glaxo, Verona, 
Italy), 12, 24 and 36,~g formoterol fumarate (Ciba, 
Basel, Switzerland) and placebo, which were all 
inhaled from a metered dose inhaler and holding 
chamber (AeroChamber) with mouthpiece, was 
investigated on several non-consecutive days. The 
subjects had not taken any inhaled bronchodilator 
drug for at least 12 h, or oral bronchodilators for 
at least 24 h before the investigation started, and 
consumption of cola drinks, coffee, tea, and smoking 
in the hours immediately before and during the 
investigation were also avoided. All experiments 
began at 8 a.m. to avoid well-known interference of 
the circadian rhythm on bronchomotor tone. 
Three acceptable forced expiratory manoeuvres 
were performed in order to obtain two reproducible 
results for FVC and FEV,. The best FVC, FEV, and 
instantaneous forced expiratory flow after SO% of the 
FVC is exhaled (FEF,,), obtained from one or the 
other of the reproducible curves, were kept for 
analysis. Measurements were performed at the fol- 
lowing times: immediately before inhalation of treat- 
ment, and at 15, 30, 60, 120, 180, 240, 300, 360, 480, 
600 and 720 min after inhalation of the individual 
treatment. 
The functional indices’ increases from baseline 
after salmeterol, formoterol and placebo were 
assessed. Comparisons of baseline characteristics 
among the three groups were performed by ANOVA 
analysis, and Fisher’s exact test. Analysis of 
spirometric data was performed using the Student’s 
t-test for paired variables. The time-averaged changes 
in the 12 h after drug administration, between each 
treatment and placebo, and between drugs were 
compared by means of the distribution free cross- 
over analysis (10). With respect to the multiple test- 
ing of three lung function parameters, the significance 
level of 0.05 was considered as relevant. The FEV, 
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Table 2 Number of patients with FEV, response to bronchodilator 15 min after inhalation 
(?I= 12) 
25 Salm 50 Salm 75 Salm 12 Form 24 Form 36 Form 
Basal FEV, range (1) 0.19-1.04 0.30-1.09 0.261.05 0.27-1.09 0.22-1.15 0.27-1.21 
PI 15% responders 8 12 11 11 10 11 
PI 25% responders 6 5 6 10 10 9 
AI responders 4 6 6 8 8 9 
Salm, Salmeterol; Form, formoterol; PI 15%, patients showing a percentage increase of > 15%; 
PI 25%, patients showing a percentage increase of >25%; AI, patients showing an absolute 
increase of > 160 ml. 
areas under the curve were analysed by the trap- salmeterol, 60-360 min; 12 ,ug formoterol, 3tL 
ezoidal rule. The baseline values were always 300 min; 24 pg formoterol, 30-360 min; 36 pug 
indicated as 100%. formoterol, 30-480 min). However, patients varied 
in their maximum response to the different doses of 
Results 
the two drugs (Fig. 1). 
All 12 patients completed the 7-day study. There TIME COURSE OF BRONCHODILATING EFFECT 
were no significant differences between the baseline The mean percent changes of FEV, from baseline 
spirometric values of the seven treatment groups after administration of salmeterol, formoterol or 
(P>O.OS). placebo are shown in Fig. 2, and the changes of FVC 
and FEF,, in Fig. 3. All doses of salmeterol and 
RATE OF ONSET OF ACTION formoterol induced a significant (PcO.01) spiromet- 
Eight out of 12 patients presented an increase ric improvement over the 12-h monitoring period 
in FEV, of at least 15%, 15 min after inhalation of when compared to that after placebo, but while 
25,ug salmeterol, 12 patients presented this increase formoterol induced a dose-dependent increase of 
after 50 pug salmeterol, 11 patients presented this FEV,, FVC and FEF,,, this was not the case for 
increase after 75 fig salmeterol, 12 pg formoterol or salmeterol. In fact, 75 pug salmeterol did not produce 
36,~~g formoterol, and 10 patients presented this a further improvement of these parameters. How- 
increase after 24 pg formoterol (Table 2). Choosing a ever, when individual subjects were considered, 
25% cut-off, six patients out of 12 responded to 25 pg there was a heterogenous response to the various 
or 75 pug salmeterol 15 min after drug inhalation, five bronchodilator regimens. A comparison of 50,ug 
patients responded to 50,~~g salmeterol 15 min after salmeterol with 12pg or 24pg formoterol (clinically 
drug inhalation, 10 patients responded to 12pg or 
24,ug formoterol 15 min after drug inhalation, and 6 
oc?-o~30 1 nine patients responded to 36,~~g formoterol after 
15 min. Using an increase in FEV, of 0.16 1 as cut-off, 5 
as suggested by Tweeddale et al. (1 l), only four out 2 4 
of 12 patients achieved such a response 15 min after 
the inhalation of 25pg salmeterol, six patients after 
.$ 
23 
inhalation of 50 pg or 75 pug salmeterol, eight patients 3 
after 12pg or 24,ug formoterol, and nine patients L? 2 
after 36 lug formoterol. 1 
MAXIMUM RESPONSE 0 
The mean individual peak bronchodilation, 25s 
expressed as the maximum increase in FEV, over 
50s 
I 
75s 12F 
Treatment 
24F 36F 
baseline values, occurred 2 h after inhalation of the Fig. 1 Maximum change in FEV, after inhalation of 
three doses of salmeterol, and 1 h after inhalation of salmeterol or formoterol for all the subjects and six sub- 
the three doses of formoterol (range 25 pg salmeterol, 
groups. 25S, 25pg salmeterol; 5OS, 50yg salmeterol; 
30-360 min; 50 lug salmeterol, 60-360 min; 75 pg 
75S, 75pg salmeterol; 12F, 12pg formoterol; 24F, 24pg 
formoterol; 36F, 36pg formoterol. 
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Fig. 2 Mean percentage changes in FEV, from baseline at 
different times after inhalation of salmeterol, formoterol or 
placebo. 0,25 ,~g salmeterol; A, 5Opg salmeterol; q ,75 ,ug 
salmeterol; 0, 12pg formoterol; A, 24,ug formoterol; 
W, 36pg formoterol; V, placebo. 
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Fig. 3 Mean percentage of changes in FVC and FEF,, 
from baseline at different times after the inhalation of 
salmeterol, formoterol or placebo. 0, 25 pg salmeterol; A, 
50 pg salmeterol; 0, 75 pg salmeterol; 0, 12 pg formoterol; 
A, 24j~g formoterol; n , 36.ug formoterol; V, placebo. 
recommended doses) showed that improvement of 
FEV, after salmeterol was statistically (PcO.05) 
higher than that after the two doses of formoterol, 
although the mean peak bronchodilations were 
similar. This was because salmeterol has a longer 
duration of action than formoterol. The highest dose 
of formoterol increased FEV, more than salmeterol, 
Fig. 4 Polynomial regression lines, order 2, for FEV, 
values. a, 25 pug salmeterol; b, 5Opg salmeterol; c, 75,ug 
salmeterol; d, 12 pg formoterol; e, 24 pg formoterol; f, 36 pug 
S25 S50 S75 F12 F24 F36 P 
Treatment 
Fig. 5. Area under the time-response curve after the 
inhalation of salmeterol (S25, S50, and S75), formoterol 
(F12, F24, and F36) or placebo (P). 
but was shorter-acting. The FEV, dose-response 
curves, shown as polynomial regression lines, 
confirmed this pattern (Fig. 4). 
FEV, AREA UNDER THE CURVES 
The mean FEV, area under the curve was signifi- 
cantly (PcO.05) larger after SOpug when compared to 
that after 12pg or 24pg formoterol (Fig. 5). How- 
ever, there was no significant difference (BO.05) 
between 50 pg salmeterol and 36 ,ug formoterol. 
Discussion 
The effects of salmeterol and formoterol on airway 
tone have been investigated in asthmatic patients. 
Ullman and Svedmyr (12) found that doses of 50 or 
100 pug salmeterol had a long-lasting effect on peak 
expiratory flow, and Derom and Pauwels (13) 
reported on the effects of prolonged bronchodilation 
after 12 or 24pg inhaled formoterol on FEV,; 
in neither of these studies did these doses have a 
dose-dependent effect. In a recent study, Rabe et al. 
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(14) demonstrated that 5Opg salmeterol and 12pg 
formoterol have a duration of action up to 24 h and 
induce bronchodilation equally effectively in patients 
with mild bronchial asthma. 
From our present study, it seems that 5Opg 
salmeterol induces a good and long-lasting broncho- 
dilation, but 75pg salmeterol does not elicit ad- 
ditional improvements in partially reversible severe 
COPD. Formoterol at doses from 12-36 pg induces a 
dose-dependent increase of bronchodilation. How- 
ever, a 5Opg salmeterol elicits a similar mean peak 
bronchodilation and a longer lasting bronchodilator 
effect than 12pg or 24pg formoterol. 
It has been previously demonstrated that sal- 
meter01 and formoterol, administered at the recom- 
mended doses for regular inhaled therapy (50,ug and 
24,ug, respectively) by metered dose inhaler, appear 
to be very effective in improving airway limitation 
in patients suffering from COPD (15). The time- 
averaged values over 12 h were significantly higher 
after salmeterol and formoterol, when compared to 
that after salbutamol and placebo, while differences 
between salmeterol and formoterol were not signifi- 
cant at any of the observed times, although there was 
a trend for a longer-lasting duration of action of 
salmeterol. The disparity between the results of that 
study and the present research could be partly 
explained by the fact that a different patient popu- 
lation was studied. Patients recruited for the first 
study had moderate COPD, whereas those in the 
present study had more severe disease, as indicated 
by their low baseline FEV, and bronchodilator 
responses at the time of initial assessment. In any 
case, the fact that only a single dose of each agent 
being compared was used, severely limited the 
information obtained. 
If a study comparing single doses of different 
agents fails to show a statistically significant differ- 
ence between the compared preparations, this is not 
equivalent to saying that they are identical. The 
failure to show a difference could be due to type 
II statistical error, i.e. insufficient sample size and, 
consequently, lack of sufficient statistical power in 
the study, or the fact that the specific subjects studied 
in the specific clinical situation in which they were 
studied were at the top of their P-agonist dose- 
response curve (16). 
A much more effective study design for comparing 
the effects of inhaled P-agonists is to use each of the 
agents being studied at various differing doses. How- 
ever, the clinical value of establishing the optimal 
bronchodilation and the optimal dose of P-agonist, 
required to produce such bronchodilation in patients 
with COPD, is limited by the large within-patient 
variability in the response to bronchodilator, result- 
ing in poor reproducibility (17). 
Lung function tests, including FEV,, PEFR and 
FVC, have been used to measure the degree of 
bronchodilation, and thereby assess bioequivalence 
and bioequipotency of inhaled drug products (18). At 
present, it is generally agreed that the acute increase 
in FEV, in response to increasing doses of @-agonist 
may be employed as the method of choosing the dose 
to be prescribed. 
One of the most common ways of expressing the 
bronchodilating response is to quantify the change 
in FEV, as a percentage of the basal obstruction 
(pre-bronchodilator FEV,). However, this change is 
strongly dependent on the initial FEV,, especially in 
patients with COPD (19). The absolute increase in 
FEV, necessary to distinguish, with 95% confidence, 
between natural variability and a response to 
bronchodilator in these patients is 160 ml (1 l), but 
even small changes in FEV, (100 ml) may be impor- 
tant to patients with severe chronic airway limi- 
tation (20). It must be highlighted that the use of a 
cut-off of 15% to define response in FEV, selects 
a greater proportion of more severely than less 
severely impaired patients (21), and our patients 
were suffering from severe obstructive ventilatory 
defects. 
In any case, if one uses a cut-off of 15%, the 
sensitivity of acute bronchodilator response in pre- 
dicting long-term symptomatic response in subjects 
with chronic airflow limitation is good, but the 
specificity is poor (21). Using higher cut-off, speci- 
ficity improves, but at the expense of sensitivity. Even 
a 15% cut-off would still leave some patients, who 
gain symptomatic benefit from the drugs, untreated. 
It is clear that an acute response to inhaled ,&agonists 
is not useful for identifying patients with chronic 
airflow limitation who are likely to benefit from acute 
bronchodilator treatment (21,22). 
In conclusion, this study has demonstrated that 
salmeterol is equally effective as, but longer-acting 
than, formoterol at clinically recommended doses in 
patients suffering from COPD, with severe airway 
limitation. This study also suggests that 5Opg is the 
best dosage for salmeterol in these patients, even 
though future bronchodilator therapy should be 
based on individual assessment, as mechanisms 
behind a similar degree of airway obstruction may 
differ. Considering that a single measurement of the 
response to a bronchodilator has limited validity, 
since short-term changes in spirometry following 
bronchodilators fail to predict the long-term 
response, controlled studies evaluating clinically 
relevant outcomes and home PEFR recordings in 
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response to different doses of salmeterol and 
formoterol over longer periods of time are needed. 
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